Modulating DDR in GBM to Enable Radiosensitizer-Driven Combination Strategies

By | 1 October 2025

• See how VSPharmTech is developing VS-101 to enable radiosensitizer-driven strategies in glioblastoma

• Clarifying synthetic lethality and combination strategies in GBM

• Exploring regulatory and orphan drug designation progress